F-18 FDG PET/CT in the management of thyroid cancer

Clinical Nuclear Medicine

Volumn 32, Issue 9, 2007, Pages 690-695

  Iagaru, Andrei ^a   Kalinyak, Judith E ^a   McDougall, I Ross ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

F 18 FDG; PET CT; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34548089877     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318125037a     Document Type: Article

References (43)

1. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
2. Spencer C. Thyroglobulin. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the Thyroid, a Fundamental and Clinical Text. 8th ed. Lippincott Williams & Wilkins; 2000;402- 413.
3. McDougall IR, Bayer MF. Follow-up of patients with differentiated thyroid cancer using serum thyroglobulin measured by an immunoradiometric assay. Comparison with I-131 total body scans. J Nucl Med. 1980;21:741-744.
4. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
5. Pineda J, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492.
6. Schlumberger M, Mancusi F, Baudin E, et al. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273-276.
7. McDougall IR. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid. 1997;7:669-672.
8. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med. 2000;30:107-114.
9. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
10. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987;28:910-914.
11. Conti PS, Durski JM, Bacqai F, et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid. 1999;9:797-804.
12. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342-1348.
13. Alnafisi N. , Driedger AA, Coates G, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000;41:1010-1015.
14. Al-Nahhas AM. FDG PET and alternative imaging in the management of thyroid carcinoma. Nucl Med Rev Cent East Eur. 2003;6:139-145.
15. Fiene ULR, Hanke JP, Wohrle H, et al. F-18DG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of F-18DG and 131I. Nucl Med. 1995;34:127-134.
16. Fiene U. Fluoro-18-deoxyglucose positron emission tomograpphy in differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:492-496.
17. Grunwald F, Biersack HJ. FDG PET in thyroid cancer: thyroxine or not? J Nucl Med. 2000;41:1996-1998.
18. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547-1552.
19. Grunwald F, Menzel C, Bender H, et al. Comparison of F-18DG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 1997;7:327-335.
20. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312-319.
21. Wang W, Macapinlac H, Larson SM, et al. [F-18]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131) I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302.
22. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [F-18]-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.
23. Wang W, Larson SM, Tuttle RM, et al. Resistance of [F-18]- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169 -1175.
24. Wu YJ, Wu HS, Yen RF, et al. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by F-18-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography. Anticancer Res. 2003;23:2973-2976.
25. Wu HS, Huang WS, Liu YC, et al. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan. Anticancer Res. 2003;23:4235- 4238.
26. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71-76.
27. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [F-18]- fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 1998;19:547-554.
28. McDougall I, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun. 2001;22:485-492.
29. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging. 2006;50:78-87.
30. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
31. Bar-Sever Z, Keidar Z, Ben-Barak A, et al. The incremental value of (18) F-FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging. 2007;34:630-637.
32. Gearhart SL, Frassica D, Rosen R, et al. Improved staging with pre-treatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol. 2006;13:397-404.
33. Halpern BS, Yeom K, Fueger BJ, et al. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007.62:199-204.
34. la Fougere C, Hundt W, Brockel N, et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2006;33:1417-1425.
35. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616-624.
36. Shammas A, Degirmenci B, Mountz JM, et al. F-18-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221-226.
37. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging. 2007;34:487-495.
38. Jeong HS, Baek CH, Son YI, et al. Integrated F-18-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf). 2006;65:402-407.
39. Karwowski J, Jeffrey RB, McDougall IR, et al. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery. 2002;132:924-928.
40. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on [(18)F-]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:641-647.
41. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:91-95.
42. Saab G, Driedger AA, Pavlosky W, et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid. 2006;16:267-272.
43. Deichen JT, Schmidt C, Prante O, et al. Influence of TSH on uptake of [F-18]-fluorodeoxyglucose in human thyroid cells in vitro. Eur J Nucl Med Mol Imaging. 2004;31:507-512.